Keywords: emea, creates, precedent, biosimilars, approvals, biogeneric, versions

EMEA creates precedent for biosimilars with approvals for biogeneric versions of Epogen

Article | 02 July 2007

Print This

Sandoz, the generics unit of Swiss drug major Novartis, has received a positive opinion from European Union regulators supporting the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in